Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An 8-week Randomized, Open-label, Multi-center Study to Evaluate the Efficacy and Safety of Oral Aliskiren 300 mg Once Daily Under Light Meal Versus Fasted Condition in Patients With Hypertension [Studio multicentrico, randomizzato, in aperto, della durata di 8 settimane per valutare efficacia e la sicurezza di aliskiren 300 mg al giorno somministrato per via orale dopo un pasto leggero rispetto alla somministrazione a digiuno in pazienti con ipertensione].

Next Previous
X
Search
Trial Profile

An 8-week Randomized, Open-label, Multi-center Study to Evaluate the Efficacy and Safety of Oral Aliskiren 300 mg Once Daily Under Light Meal Versus Fasted Condition in Patients With Hypertension [Studio multicentrico, randomizzato, in aperto, della durata di 8 settimane per valutare efficacia e la sicurezza di aliskiren 300 mg al giorno somministrato per via orale dopo un pasto leggero rispetto alla somministrazione a digiuno in pazienti con ipertensione].

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 07 Nov 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Aliskiren (Primary)
  • Indications Essential hypertension
  • Focus Therapeutic Use
  • Sponsors Novartis Pharmaceuticals

    • Most Recent Events

    • 01 Nov 2012 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
    • 02 Apr 2012 New source identified and integrated (ClinicalTrials.gov: US National Institutes of Health; NCT01570686).
    • 02 Apr 2012 Planned end date 1 Dec 2012 added as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top